Back

‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies

European Heart Journal

11 December 2017
Organised by: Logo
Read full article
ESC Journals PREVENTIVE CARDIOLOGY Risk Factors and Prevention

Contributors

Lieven Annemans
Lieven Annemans

Author

Ghent University Ghent , Belgium

Chris J Packard
Chris J Packard

Author

Andrew Briggs
Andrew Briggs

Author

Kausik K Ray
Kausik K Ray

Author

You may be interested in
thumbnail
Congress Presentation
Evaluating risk-based allocation strategies for PCSK9 inhibitors: results from a simulation study in a contemporary ASCVD cohort
26 August 2023
thumbnail
Congress Presentation
Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease
29 August 2020
thumbnail
Webinar
Post-ACS management of dyslipidaemia: tips and tricks from real world experiences
16 December 2020
thumbnail
Congress Presentation
Review on clinical strategies for managing patients with elevated Lp(a): Cost-effectiveness of Lp(a) testing and awareness of lifestyle changes via Public Health Policy in absence of targeted therapy
24 June 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources